Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus.

Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, NSW, Australia.
The Medical journal of Australia (Impact Factor: 2.85). 09/2009; 191(6):339-44.
Source: PubMed

ABSTRACT Tight glycaemic control reduces the risk of development and progression of organ complications in people with type 1 or type 2 diabetes. In this position statement, the Australian Diabetes Society recommends a general target glycated haemoglobin (HbA(1c)) level of </= 7.0% for most patients. This position statement also provides guidelines for the individualisation of glycaemic targets to a tighter or lesser degree, with a recommended target HbA(1c) level of </= 6.0% in some people, or up to </= 8.0% in others. Individualisation of the HbA(1c) target is based on patient-specific factors, such as the type of diabetes and its duration, pregnancy, diabetes medication being taken, presence of cardiovascular disease, risk of and problems from hypoglycaemia, and comorbidities. Management of diabetes also includes: adequate control of other cardiovascular risk factors, including weight, blood pressure and lipid serum levels; antiplatelet therapy; and smoking cessation.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Aim To assess the cost-effectiveness of an automated telephone-linked care intervention, Australian TLC Diabetes, delivered over 6 months to patients with established Type 2 diabetes mellitus and high glycated haemoglobin level, compared to usual care. Methods A Markov model was designed to synthesize data from a randomized controlled trial of TLC Diabetes (n = 120) and other published evidence. The 5-year model consisted of three health states related to glycaemic control: ‘sub-optimal’ HbA1c ≥58 mmol/mol (7.5%); ‘average’ ≥48-57 mmol/mol (6.5- 7.4%) and ‘optimal’ <48 mmol/mol (6.5%) and a fourth state ‘all-cause death’. Key outcomes of the model include discounted health system costs and quality-adjusted life years (QALYS) using SF-6D utility weights. Univariate and probabilistic sensitivity analyses were undertaken. Results Annual medication costs for the intervention group were lower than usual care [Intervention: £1076 (95%CI: £947, £1206) versus usual care £1271 (95%CI: £1115, £1428,) p = 0.052]. The estimated mean cost for intervention group participants over five years, including the intervention cost, was £17,152 versus £17,835 for the usual care group. The corresponding mean QALYs were 3.381 (SD 0.40) for the intervention group and 3.377 (SD 0.41) for the usual care group. Results were sensitive to the model duration, utility values and medication costs. Conclusion The Australian TLC Diabetes intervention was a low-cost investment for individuals with established diabetes and may result in medication cost-savings to the health system. Although QALYs were similar between groups, other benefits arising from the intervention should also be considered when determining the overall value of this strategy.
    Diabetes research and clinical practice 01/2014; · 2.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To reduce the congenital malformations that occur in pregnancies complicated by diabetes, it is essential to achieve and maintain a good metabolic control before conception. In this context, measuring HbA1c is considered as the gold standard for monitoring metabolic control in diabetes and various different HbA1c levels have been recommended as optimal in the preconception period for diabetic women planning a pregnancy. An analysis of key studies published on this issue until now clearly shows that HbA1c levels correlate closely with the occurrence of congenital malformations and other neonatal complications characteristic of pregnant diabetic women. HbA1c is therefore one of the key markers to use in monitoring metabolic control, and the most reasonable approach would seem to be to use a standardized measurement method and aim for HbA1c levels resembling normal values as closely as possible, with a view to preventing episodes of hypoglycemia.
    Acta Diabetologica 09/2010; 47(3):187-92. · 4.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The diabetes epidemic imposes a substantial burden on health systems and economy all over the world. Over the last two decades many health systems adopted healthcare quality and performance measures for DM most notably hemoglobin A1C (HbA1c). This article raises concerns regarding the significance of HbA1c as a performance measure and emphasizes the need for individualized therapy. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 02/2014; · 2.97 Impact Factor

Full-text (2 Sources)

Available from
May 16, 2014